Search results
Showing 1 to 15 of 18 results for carfilzomib
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.
NICE is unable to make a recommendation on isatuximab (Sarclisa) with carfilzomib (Kyprolis) and dexamethasone for treating relapsed or refractory multiple myeloma because Sanofi did not provide an evidence submission.
Show all sections
Sections for TA727
NICE is unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA841
In development Reference number: GID-TA11203 Expected publication date: 30 April 2026
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.
We are listening to your views on this Technology appraisal guidance. Comments close 16 April 2026.
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Awaiting development Reference number: GID-TA11752 Expected publication date: TBC
Awaiting development Reference number: GID-TA11660 Expected publication date: TBC
Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]
Discontinued Reference number: GID-TA11210